Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/S576 enrolled

Overview

This trial is conducted in the United States of America (USA) and Canada. This trial is designed to show the effect of treatment with liraglutide when added to existing rosiglitazone and metformin combination therapy and to compare it with the effects of therapy with rosiglitazone and metformin alone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

576

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

liraglutideDRUG

rosiglitazoneDRUG

metforminDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Type 2 diabetes * Treated with oral anti-diabetic (OAD) drugs for at least 3 months * Treated with one or more OAD and in moderate to poor glycemic control * Body Mass Index (BMI) less than or equal to 45.0 kg/m2 Exclusion Criteria: * Treatment with insulin within the last three months prior to the trial except due to intercurrent illness, at the discretion of the Investigator * Any serious medical condition * Treatment with any drug that could interfere with glucose level

Locations (89)

Outcomes

Primary Outcomes

HbA1c

Time frame: after 26 weeks of treatment

Secondary Outcomes

body weight

Safety and tolerability

Glycaemic control

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.